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Abstract 
Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 
30% of global deaths. Despite the improved clinical management, cardiovascular mortality is 
predicted to rise in the next decades due to the increasing impact of aging, obesity and 
diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD 
using nanoscale medical products and devices. However, the development of novel 
multicomponent nano-sized products poses multiple technical, ethical and regulatory 
challenges, which often obstruct their road to successful approval and use in clinical practice. 
This review discusses the rational design of nanoparticles, including safety considerations and 
regulatory issues, and highlights the steps needed to achieve efficient clinical translation of 
promising nanomedicinal products for cardiovascular applications. 
 
Keywords: Cardiovascular nanomedicine; clinical translation; nanoparticle design; 
nanosafety; regulatory issues.  
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1. Introduction 
Cardiovascular nanomedicine aims to improve diagnosis and treatment of cardiovascular 
diseases (CVD), which are responsible for the majority of deaths worldwide 1. Regarding 
diagnostics, the goal is to move the current imaging agents to a new level allowing the 
detection and characterization of CVD at an early stage. The therapeutic aim is to move 
forward from conventional drug therapies that lead to full systemic exposure to targeted drug 
delivery using nanosystems that minimize the systemic side effects and enhance drug 
localization and efficacy in atherosclerotic and thrombotic lesions. With hybrid nanoparticles 
(so called “theranostics”) one could combine imaging and treatment, to enable monitoring 
patients’ responses to therapy. 
The possible applications of nanoparticles in the management of CVD range from ultra-
sensitive monitoring of cardiovascular markers, through detection and characterization of 
plaques and aneurysms, in situ detection of thrombosis, imaging of inflammation in 
myocardial infarction (MI), to the targeted delivery of atheroprotective or thrombolytic drugs  
(Fig. 1) 2-10. Cell labelling with nanoparticles for cell-based therapies can also be envisioned 
to enhance stent endothelialisation and improve myocardial regeneration 11-13.  
However, bringing a medicinal product into the clinical arena is a challenging and time/cost-
consuming process. Extensive in vitro and in vivo preclinical studies are required before first-
in-man clinical safety trials can be initiated. In the USA, the Food and Drug Administration 
(FDA) is the responsible supervising agency to decide if a drug or a medical device is allowed 
to enter clinical trials and whether, upon completion of the clinical development program, it 
will be approved for marketing. In Europe, the European Medicines Agency (EMA) is the 
regulatory body responsible for drug market approval. The classical process of drug 
development, testing and approval is estimated to take around 10-15 years, with costs of 
roughly around 1 billion USD per product according to some estimates 14. Both the EMA and 
the FDA have stated that no new regulations are needed for approval or commercialization of 
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nanomedicines, considering that the existing regulatory framework is valid and accurate. 
There is, however, a need for elaboration of the regulatory framework to accommodate for 
special safety and quality aspects that complex nanotechnology products can entail, and a 
need to improve technical guidance documents used for the application and implementation of 
existing regulatory frameworks 15.  
A standardized definition of “nanoparticle” varies among organizations and countries. 
Although a specified size limit is not always relevant for scientific or medical applications, it 
is needed for regulatory purposes and is defined (albeit differently) both in the EU and in the 
USA. The definition implemented in the EU states that nanomaterial is a “natural, incidental 
or manufactured material containing particles, in an unbound state, or as an aggregate, or as 
an agglomerate and where, for 50% or more of the particles in the number size distribution, 
one or more external dimensions is in the size range 1–100 nm”, but exceptions are possible 
to the percentage and the upper limit of 100 nm, especially in the pharmaceutical sector 16. 
The FDA defines nanomaterial as any material with at least one dimension smaller than 1000 
nm and a nanoparticle as an object with all three external dimensions in the 1-100 nm size 
range. 
Despite the costs and regulatory obstacles, about 250 nanomedicinal products, mostly for 
cancer treatment, were listed by FDA as approved, or were in different phases of clinical trials 
in 2013 17, whereby the market is dominated by liposomal and polymeric nanomedicines 14, 17, 
18. Medicinal nanosystems in the form of e.g. liposomes (i.e. Doxil®, AmBisome®), or PEG-
conjugated proteins (Adagen®, Neulasta®) have already been granted marketing authorisation 
within the EU and the USA under the existing pharmaceutical legislation. As for any 
medicinal product, the authorities evaluate any marketing application by the established 
principles of benefit/risk analysis, rather than solely on the basis of the technology per se. The 
majority of nanosystems approved thus far were relatively simple and aimed at improving 
stability, half-life, bioavailability and safety of existing drugs. It is likely that some new 
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nanotechnology products that reach clinical trials will gain in complexity, as the technology 
gradually advances and treatment goals become ever more ambitious. According to the 
current EU directives, the decision whether a nanomedicinal product is a medicine or a 
medical device, which determines the applicable regulatory regime, is based on the principal 
mode of action. With medical devices, the mode of action is physical (mechanical or 
chemical) while a medicinal product acts by pharmacological, immunological or metabolic 
means 19. However, future nanomedical products may span the regulatory boundaries between 
medicinal products and medical devices, and for those nanomedicines which have a complex 
mode of action, this decision may prove difficult as their activity might depend on both 
physicochemical/mechanical and pharmacological properties 20, 21.  
 
 
 
Figure 1. Possible applications of nanoparticles (NP) for diagnosis and therapy in CVD 
patients.  
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As compared to the vast number of experimental research reports focusing on cardiovascular 
applications of nanoparticles that have been published in the recent years (reviewed in 22-25, 
the reported clinical trials remain very scarce in this field. This is likely due to the rational 
design of non-cytotoxic nanosystems and hurdles related to scale up, GMP-grade production, 
quality control and full preclinical assessments which are required before clinical studies can 
be started (Fig. 2). Based in particular on the experience from the European Commission 
funded NanoAthero project (“Nanomedicine for target-specific imaging and treatment of 
atherothrombosis - Development and initial clinical feasibility” http://www.nanoathero.eu/), 
this review addresses the main translational steps and challenges that cardiovascular 
nanomedicines encounter on their development from bench to bedside. 
 
 
Figure 2. Clinical translation scheme. In vitro studies on imaging and drug-delivery 
nanosystems produced in the laboratory scale represent the largest shelves in the pyramid. 
The number of nanomedicinal products reaching and passing the regulatory and toxicological 
hurdle to enter clinical trials remains very low. 
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2. Translation hurdle: Clinical trials in cancer versus cardiovascular diseases  
The search for clinical trials on the homepage clinicaltrials.gov of the US government dealing 
with "nanoparticles" and "cardiovascular diseases” delivered 13 results, whereas the search 
for "nanoparticles" and "cancer" lists 176 performed or ongoing clinical trials. Although not 
all clinical trials can be found on clinicaltrials.gov, this indicates the considerable challenge in 
putting cardiovascular nanomedicines on the road to clinical trials as compared to anti-cancer 
nanodrugs. The 13 listed CVD trials include contrast agents for improved imaging of 
cardiovascular inflammation and enhanced diagnosis of acute coronary syndrome, nanodrugs 
for prevention of restenosis after revascularization, as well as plasmonic photo-thermal 
therapy (PPTT) of atherosclerotic plaques. Among the completed and published trials, several 
were related to the clinical use of iron oxide nanoparticles for improved detection and 
characterization of atherosclerotic plaques (ferumoxtran (Sinerem®), 26-28), or aortic 
aneurysms (ferumoxtran (Sinerem®), 5) and detection of inflammation in myocardial 
infarction (ferumoxytol (Feraheme®) 29-31). Recently, in association with the NanoAthero 
project, a clinical study was done by the group of E. Stroes et al., investigating the utility of 
ferumoxytol for carotid plaque imaging 32. Concerning therapeutic application of 
nanoparticles in CVD, only a few studies have been reported so far. Some examples are thus 
briefly highlighted. In the BLAST trial, the safety and anti-restenotic efficacy of a single 
intravenous bolus of liposomal alendronate, which transiently modulates monocyte function, 
was examined in patients undergoing bare metal stent placement 33. An angiographic 
assessment of late lumen loss at 6 months post implantation demonstrated that the treatment 
effectively reduced the late loss in the inflammatory patient subgroup, but not in the entire 
liposomal treatment cohort. The NANOM first-in-man trial, published in 2015, investigated 
the feasibility of atherosclerosis treatment by reducing the total atheroma volume with PPTT 
34. Silica-gold nanoparticles with photothermal properties were delivered on bioengineered 
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artery patch containing stem cells, or via an intravenous catheter under magnetic guidance, 
followed by irradiation using near-infrared laser 34. This clinical trial showed that both forms 
of administration were superior to stenting and that photothermal destruction of atheroma 
tissue resulted in a reduction of the plaque volume down to 37.8% of initial plaque burden, 
whereas stenting resulted in 52.9% reduction of plaque burden 34. It is however questionable, 
to what extent this technique may prove applicable in the clinical routine everywhere. Within 
the NanoAthero project, a clinical trial was also performed to test the treatment of 
atherosclerotic plaques with a targeted nanomedicine containing prednisolone (Nanocort®). In 
that study, prednisolone was encapsulated into liposomal nanoparticles, which increased the 
plasma half-life of the drug 35. After systemic intravenous infusion in an antecubital vein, it 
was demonstrated that the nanoparticles were localized in the macrophages isolated from 
atherosclerotic plaques harvested from the iliac arteries, thereby lending proof-of-concept that 
intravenous liposomes can successfully target inflammatory cells within the atheroma. The 
clinical studies did not demonstrate that the delivered prednisolone have an anti-inflammatory 
effect measured by PET imaging in the atherosclerotic lesions 36, which might be related to in 
vitro observations that macrophages become lipotoxic, exemplified by enhanced lipid loading, 
ER stress and apoptosis 37. Summarizing the previous clinical trials, it is clear that the 
application of nanomedicine in CVD patients is still in its infancy and great effort will likely 
be needed to enforce a clinical breakthrough. 
 
3. Rational design of nanosystems: Safety by design  
Imaging is a crucial aspect for risk stratification as well as for the selection of subsequent 
therapy and follow-up monitoring. Nanoparticulate contrast agents have been shown to 
improve the detection and characterization of CVD, but their application in potentially healthy 
subjects raises a particularly high safety hurdle. Nanoparticle-based drug delivery systems are 
an attractive platform to improve the efficacy and reduce the systemic toxicity of 
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cardiovascular drugs. For therapeutic applications, novel nanoparticle formulations including 
drug-carrying liposomes, lipid nanoparticles, superparamagnetic iron oxide nanoparticles 
(SPIONs) and polyacrylates are currently being developed by our groups and others 35, 38-43. 
Additional modifications, including functionalization with targeting ligands and/or imaging 
agents are often necessary to locally deliver the therapeutic nanoparticles and to monitor the 
effect of the treatment. This can result in a complex multicomponent nanosystem (Fig. 3), 
which will require many synthesis and manufacturing steps as well as a range of quality 
controls, which leads to a tremendous cost increase 44. 
 
 
Figure 3. Example design of nanoparticles to achieve a targeted drug delivery and/or imaging 
agent. Due to the small size of nanoparticles, their surface area is large. This provides various 
possibilities of surface modifications e.g. by coating in order to stabilize and prevent 
aggregation of nanoparticles, and to allow conjugation of ligands or drugs.  
 
 
A more rational design of the particles may partly help to reduce costs and increase chances 
of achieving successful clinical translation. Setting aims, i.e. selecting the disease process to 
be addressed and the intended application of nanosystem (diagnostics vs therapeutic) is the 
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first step in the development process. The design and production at the lab scale must be 
followed by a complete physicochemical characterization of nanosystems, using the available 
specifically adapted evaluation methods 45, 46. As different techniques for nanoparticle 
characterization are available (e.g. transmission electron microscopy, Fourier transform 
infrared spectroscopy, dynamic light scattering), each of them featuring its own advantages 
and limitations, the characterization data obtained with several different measurement 
methods should be compared to ensure reliable results.  
In-house physicochemical characterization and storage stability evaluation of produced 
batches limits the costs in the early development stage. Within the NanoAthero project, 
nanoparticle characterization and stability evaluation were performed in parallel in-house by 
nanoparticle providers and also by a selected independent partner, in order to demonstrate 
comparability and allow for reproducibility validation. In this respect, the Nanotechnology 
Characterization Laboratory (NCL) in the US (https://ncl.cancer.gov/), and more recently its 
European counterpart, European Nanomedicine Characterization Laboratory (EU-NCL, 
http://www.euncl.eu/), provide independent trans-disciplinary testing infrastructures covering 
a large set of preclinical validated characterisation assays (physical, chemical, in-vitro and in-
vivo biological testing). 
Among the parameters to consider when designing a nanosystem is the chemical composition, 
which is often the most critical feature that affects nanoparticle toxicity 47, 48. Further, particle 
surface charge, indicated by zeta potential, has a strong influence on nanoparticle stability in 
suspension and in vivo toxicity 49, 50. Size is another critical factor that affects the behavior 
and biological safety of nanoparticles 51. For example, nanoparticles with hydrodynamic 
diameter smaller than 10 nm have been reported to cause undesirable effects by passing 
through the blood-brain barrier, and nanoparticles with diameter less than 5 nm are rapidly 
cleared by the kidneys, which dramatically reduces their circulation time 50. Particle size and 
shape are also likely to affect their margination, extravasation and penetration through 
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vascular walls, particularly in larger vessels relevant to cardiovascular diseases (reviewed in 
52, 53). Previous ex vivo studies in whole blood model showed enhanced margination of micro- 
compared to nano-sized particles and the dependence of this effect on a high aspect ratio of 
particles 54, 55. In these investigations, nanorods did not display enhanced margination 
compared to nanospheres 55, indicating that binding of nanoparticles to arterial endothelium 
may require a margination-enhancing design and/or active targeting. Nanoparticle 
agglomeration is another factor with strong adverse consequences in vivo 56. Agglomeration is 
influenced by the particle composition, size and zeta potential, but also extrinsic factors, e.g. 
temperature, as well as pH, osmotic strength and the presence of serum. As aggregated 
nanoparticles are no longer nano-sized, they undergo a rapid recognition by the 
reticuloendothelial system (RES) and are cleared by the liver or spleen. Moreover, their 
presence in the circulation may cause serious undesirable side-effects, such as clogging blood 
or lymphatic vessels 57. Prevention of agglomeration is therefore required for designing a 
stable, clinically safe nanosystem. In this respect, PEGylation of nanoparticles appears 
effective in reducing their agglomeration. By creating a hydrophilic layer around the 
nanoparticles, PEGylation also provides a strong steric barrier to opsonin adsorption 58, 
opposing nanoparticle recognition by the RES and increasing their circulation half-life. Other 
methods to reduce particle agglomeration explored within the NanoAthero project included 
coating of SPIONs with crosslinked dextran or fatty acids 42, 59 and brush-like coating of 
polymer nanoparticles with polysaccharides (dextran and fucoidan, 8). Careful attention 
should also be given to the protein corona which forms on the surface of the nanoparticles 
when they interact with plasma, since this can affect their toxicity and efficacy 60, 61. Taken 
together, detailed and standardized characterization can facilitate the prediction of 
nanoparticle performance in physiologic conditions and is mandatory to consider before any 
given nanosystem can enter the preclinical in vitro and in vivo testing stages.  
 
CVR-2018-481-R1 
12 
 
4. Candidate selection: A multi-criteria decision process 
In the selection of the best candidate nanosystems for imaging and therapy of 
atherothrombosis many factors should be carefully considered. Within the NanoAthero 
project, a decision tree was established based on the physical and biochemical characteristics 
of the nanosystems developed in this project (Fig. 4). The most important selection criteria are 
briefly outlined below with short commentaries.  
(a) Product physicochemistry 
Physicochemical properties of the nanoparticles are the critical determinants of their safety 
and in vivo performance. Intensive efforts are being developed by the NCL and EU-NCL 
initiatives, as well as by different research groups, including the NanoAthero consortium, to 
propose standardized methods for measurements of key parameters such as particle diameter 
and zeta potential 62-64. Apart from the parameters listed in the paragraph 3 (diameter, charge, 
polydispersibility), pH and osmolarity of the final dispersion for long-term storage and for 
injection should be considered when selecting suitable candidates. In case of nanosystems 
containing drugs or contrast agents, encapsulation/binding efficiency and the amount of drug 
or contrast agent per particle are the important selection parameters.  
(b) Ingredient quality (safety, sterilisability, pyrogen content) 
The quality of the starting materials is an important point to be considered. Preferably, raw 
materials with existing pharmacopeia reference (i.e., Ph.Eur., USP) or medical-grade 
substances should be used for nanoparticle synthesis. The safety of ingredients can be 
confirmed using the GRAS (Generally Recognized as Safe) Substances Database 
(https://www.accessdata.fda.gov/scripts/fdcc/?set=SCOGS). 
The final drug product should obviously be sterile. Sterilisability of the produced 
nanoparticles must therefore be ensured, which is in most cases achieved with (redundant) 
sterile filtration through < 0.2 micrometer filters right before filling into the sterile dosage 
units. Depending on the chemical/biological components and the production process, the final 
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nanosystem may contain bacterial endotoxins 65, which can cause adverse effects upon in vivo 
administration, potentially leading to the organ damage. The FDA-recommended high-
sensitivity bacterial endotoxin LAL test (limulus amoebocyte lysate assay) is commonly used 
in preclinical pharmaceutical development, but many nanoparticles interfere with the assay 65, 
66. In our project, there was a case of endotoxin contamination of an additive, the 
commercially available bovine serum albumin (BSA) used as a coating to improve the 
biocompatibility of one type of SPIONs. This resulted in unexpected inflammatory effects of 
these particles and additionally necessitated a complete and very costly purification of the 
synthesis unit to avoid cross-contamination. To overcome this problem, clinical grade serum 
albumin of human origin was used for further development of these particles. 
(c) Manufacturability (process, cost of goods) 
The manufacturing process of a nanomedicinal product may involve a multi-step procedure 
requiring a number of excipients, which can drastically increase the cost and represents an 
additional production hurdle. The research and development methods often involve a low 
volume production and scaling up the process may entail serious difficulties for some 
nanoparticles, and be easier for others 67. For instance, scaled-up production of lipid 
nanoparticles is relatively easy to implement, and has been documented for more than 25 
years in the medical field 68. Apart from this, the costs and availability of raw materials must 
be considered, as well as the batch-to-batch reproducibility of physicochemical 
characteristics. 
(d) Stability 
Although it is not strictly required for human application, long term stability on storage of 
nanosytems is a prerequisite for a nanoproduct to be marketable. Ideally, the shelf life should 
be equal to or longer than 6 months. The parameters to consider include colloidal stability and 
chemical stability of drugs and excipients on storage, but also potential leakage of drug or 
contrast agent from the nanoparticles. Within NanoAthero, the standardised physicochemical 
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characterization of nanosystems was performed at 1 month post preparation date and - to 
determine the long-term particle stability - the subsequent measurements were performed after 
3, 6 and 12 months of storage at 4 °C in the respective nanoparticle dilution media. The 
acceptable variation was set to 10% diameter variation, and 20% polydispersity index 
variation at PDI of maximally 0.25. 
(e) Toxicity/Biocompatibility 
One of the factors that may influence the particle behavior and toxicity is stability in 
biological fluids (serum-containing cell culture media, plasma, whole blood) 69. Analysis of 
nanoparticle agglomeration in plasma and blood is therefore mandatory. The screening of 
nanosystems should first be done in vitro, to assess the potential toxicity of nanoparticles 
towards blood cells, other first-contact cells (e.g. endothelial cells in the case of intravenous 
application) and the actual target cells. Other undesired effects, including hemolytic reactions, 
platelet and complement activation, reactive oxygen species production can relatively quickly 
be evaluated by in vitro tests 42, 70. After in vitro screening to select the constructs with 
adequate hemo- and biocompatibility, proof of principle studies in in vivo models and GMP-
compliant manufacturing process are required, that are followed by regulatory toxicity studies 
in animals, usually rats and mice (see paragraph 6 below) 71. 
 (f) Efficacy 
To some extent, the in vivo performance and potential efficacy of nanosystems can be 
predicted with in vitro or ex vivo models or phantoms 42, 72, 73, but the ultimate preclinical 
proof of efficacy requires an animal model of disease. In the NanoAthero project, the 
characterized nanosystems containing imaging agents (radionuclides, iron oxides, micellar 
formulations containing gadolinium) were tested in appropriate animal models: mouse or 
rabbit models of atherosclerosis and a rat model of thrombosis 8. Dedicated small animal MRI 
coils and a 3T MRI system were used for imaging. To verify the accumulation of the 
nanosystems in the diseased region, histological analysis of the imaged sections was 
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performed post mortem. SPECT/CT and PET analysis, including the grafting of tracers was 
also performed, as well as in vivo and ex vivo fluorescence imaging after nanoparticle 
labeling.  
For therapeutic purposes, the nanosystems containing compounds with anti-inflammatory 
activity were pre-screened in vitro 72 and then tested in the apolipoprotein-E (apoE)-knockout 
mouse model 39, followed by selection of promising candidates.  
(g) Pharmacokinetics (PK) and biodistribution 
The determination of pharmacokinetics and biodistribution is usually done by the detection of 
particle- and/or drug-bound radiolabels in animal tissues harvested at different time points. 
Radiolabelling (3H or other radionuclides) allows imaging of the biodistribution of 
nanoparticles on tissue sections in rodents and the quantification of the percent of injected 
dose in different organs and body fluids. Full-body autoradiography or selected tissues 
sampling for well counting should identify the main targeted organs (usually liver, kidney, 
spleen). Biodistribution estimation derived from in vivo nuclear imaging using nanopaticles 
labeled with gamma- or positron-emitters radionuclides is an alternative. While the accuracy 
of the measurement is lower compared to direct tissue sampling, this approach allows for 
iterative assessments in a single animal, enabling either a marked reduction of the number of 
animals sacrificed for a given experimental protocol, and/or an increase in the number of 
measurements 74. Fluorescence imaging, having the advantages of lower cost, detection below 
cellular level by microscopy techniques, is another alternative, but its main limitation is that it 
is not truly quantitative (semi-quantitative analysis). 
In case of nanoparticles containing a drug payload, the drug can be labeled with 14C. By using 
dual 14C and 3H-detection, parallel quantification and comparison of the biodistribution 
between the free drug and nanoparticle-conjugated drug is possible 43, 75. Ex vivo validation by 
autoradiography allows localizing a radioactive material within particular tissues or cells with 
high sensitivity and quantitative estimation of the delivered amount of (nano)drug 76, 77.  
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These data are of critical importance to determine the ability of nanoparticles to target and 
deliver their drug payload to particular tissues, but the expense and the efforts required for 
these investigations are considerable.  
 (h) Clinical « acceptability » 
Novel nanodrugs are commonly greeted with a degree of concern and reserve in fear of their 
potential nanotoxicity, unless the nanosystem carrier is well-established and/or carries an  
approved drug. Acceptance is usually less of an issue in high-medical-need indications 78. 
Quite obviously also the administration route is a factor of importance, whereby oral 
administration is preferred by patients 79.  
However, parenteral administration and in particular intravenous injection is often the only 
feasible way cardiovascular contrast agents and nanodrugs should be given, which requires 
admission of a patient to a hospital or outpatient clinic, and significantly increases the costs. 
 
Figure 4. Candidate selection criteria. ADME, absorption, distribution, metabolism and 
elimination; GRAS, generally recognized as safe; PDI, polydispersity index. 
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5. In vitro proof of safety and efficacy 
 
Nanomedicine offers unique possibilities in terms of cardiovascular disease management, but 
despite these exciting possibilities, it is clear that nanomedicines can also entail new and 
sometimes unforeseen risks. The impact of nanoparticles on biological pathways and their 
toxic effects on the human body can be difficult to predict. Due to the interference of the 
particles with the traditional photometric cytotoxicity assays, routinely used tests such as 
lactate dehydrogenase (LDH) assay or 3-(4,5dimethylthiazol-2-yl)2,5diphenyltetrazolium 
bromide (MTT) assay can produce false-positive or false-negative results 80, 81. Toxicity of 
engineered nanoparticles can be over- or underestimated due to their influence on absorbance 
of light in the visible spectrum, quenching of fluorescence or even adsorption of the dye to 
their surface 81. Suitable in vitro assays must thus be chosen and validated to enable a 
meaningful in vitro toxicity evaluation. Several organizations, including the NCL or the 
International Organization for Standardization (ISO) underscore the importance of a general 
standardization of in vitro toxicity assessment within nanotechnology and nanomedicine 45. 
An essential point here is the batch-to-batch reproducibility, because safety or efficacy 
evaluations are not reliable if batch-to-batch reproducibility is insufficient. 
Full biocompatibility (including hemo- cyto- and immune compatibility) of the nanosystems 
is absolutely essential, as the target population of CVD patients may be prone to critical 
responses to any incompatibility. Therefore, developing a systematic workflow to analyse the 
biological effects of nanoparticles under standardised conditions is particularly relevant. All 
nanosystems intended for intravascular administration should be tested for their potential 
toxicity towards primary human endothelial cells. Using two complementary methods for 
long-term in vitro monitoring in parallel is recommended, as one single method may increase 
the risk of bias. In our opinion, real-time cell analysis and live-cell microscopy represent the 
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suitable methods for parallel testing of the toxicity of nanoparticles in static in vitro 
conditions 64. Importantly, no interference resulting from the presence of nanoparticles should 
be detectable by real-time cell analysis in the absence of cells, which was indeed the case in 
our studies. This clearly underscores the suitability of the techniques we used for the future 
standardised nanotoxicology studies. Beyond analysis of nanoparticle effects on cell viability 
in static culture conditions, investigating the effects of circulating nanoparticles on endothelial 
monolayer under physiologic-like shear stress conditions allows performing the in vitro 
assays in dynamic conditions corresponding to the physiological environment of endothelial 
cells 64. Among the nanosystems evaluated positively in cell-compatibility studies, selected 
candidates should undergo detailed analyses to exclude hemolysis, coagulation, platelet 
activation and aggregation, leukocyte activation, and complement activation 42. 
Concerning possible compounds in evaluation for therapeutic applications, an in vitro 
screening setup for selected promising compounds/formulations and their potential athero-
protective effects should be established. For instance, within NanoAthero we selected a range 
of in vitro assessments that address several pivotal pathologic pathways in atherosclerotic 
plaques. These assays revealed that pterostilbene, simvastatin, and the liver X receptor (LXR) 
agonist T0901317 were the most promising atheroprotective compounds to be integrated into 
nanosystems for plaque therapy 72 and three simvastatin-loaded nanocarriers, including high-
density lipoprotein nanoparticles, PEGylated liposomes, and polymeric micelles, were 
subsequently evaluated in vivo, in apoE-deficient mice 39. 
 
6. Preclinical animal models 
Multiple animal models are available that address CVD in different species, including rodents 
and larger animals (rabbits, pigs, non-human primates) 82, 83. To date, genetically-engineered 
hyperlipidemic mice are among the most widely used models of atherosclerosis, but several 
transgenic models in alternative species (rat, pig) have also been created 84, 85. While mouse 
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models of atherosclerosis are inexpensive and highly valued as a tool to identify the molecular 
mechanisms of the disease that can be targeted by novel (nano)medicines, they lack 
multifactorial background of atherosclerosis and have limited predictive value as the lipid 
profile and metabolism of mice, as well as the plaque composition are different from humans 
86. Additional drawback is the small size of these animals, which limits the availability of 
biological samples, as well as the possibility of morphological and functional imaging of 
atherosclerosis. Despite of these drawbacks, mice still represent a model of choice for initial 
drug testing or biodistribution studies, and the continuing efforts to develop transgenic 
models, e.g. apoE3Leiden/cholesteryl ester transfer protein (CETP) mice 87, aim at better 
reproduction of human disease characteristics.  
To promote clinical translation of emerging nanomedicinal products, larger animal models 
suitable for interventional procedures and imaging are advantageous. Rabbits represent a cost-
efficient model of atherosclerosis with similarities to human lipoprotein profile, CETP 
expression, and size large enough to allow tissue sampling and imaging in clinically used 
scanners. The limitation of the rabbit model is that lesion complications observed in humans 
(hemorrhage, ulcerations, thrombosis) are usually absent and their foam cell and macrophage 
load is increased compared to human plaques. Pigs and non-human primates represent two 
atherosclerosis models considered optimal to reflect the disease in patients, because of their 
similarities to humans in terms of metabolism, cardiovascular anatomy and physiology. 
Human-like complex plaque morphology 88 and instability traits have been reported in these 
animals 89, 90.  Despite the disadvantages of the large animal models, including the great 
expense and ethical considerations, these models allow the best extrapolation of findings to 
humans, thus contributing to the development of emerging therapies. 
Detailed recommendations on design and performing animal studies in common models of 
atherosclerosis have been recently published in a statement of American Heart Association 83. 
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7. In vivo safety: A prerequisite for approval 
Toxicology assessment of nanomedicines in vivo is in principle not very different from 
conventional drug products, albeit that specific potential nanomedicine-related safety issues in 
humans need to be looked for in special animal models. These are listed below.  
(A) Complement activation-related pseudoallergy (CARPA) assessment: To characterize, 
predict and prevent pseudoallergic reactions to nanomedicines, which often arise following 
their first intravenous administration, EMA recommends the detection of the complement 
activation-related pseudoallergy (CARPA). The unique in vivo porcine model of CARPA 
allows evaluation of the risk of - otherwise unpredictable - acute cardiopulmonary distress, 
which can be severe or occasionally lethal, and therefore unacceptable for CVD patients 91. 
The CARPA tests in pigs should include both single dose and repeat-dose administration, 
corresponding to the predicted use of the final nanosystem 92. The candidates that passed the 
CARPA evaluation successfully without inducing hypersensitivity reaction (i.e. were 
CARPA-negative) can subsequently enter the regulatory toxicity studies 42, 70. 
Additionally, many nanomedicines undergoing development or approved as products include 
a coating to improve stability, minimize aggregation and prolong circulation time. The 
presence of coating has the potential to impact on bio-molecular and cellular interactions of 
nanoparticles upon in vivo administration. For example, naturally occurring anti-PEG 
antibodies (IgM) have been detected in nearly 25% of healthy donors with no known 
exposure to PEG, indicating a growing prevalence of PEG exposure (e.g. in cosmetics or 
processed foods) and an increased risk of immunogenicity/antigenicity 93. Anti-PEG 
antibodies may also lead to increased clearance of PEGylated nanomedicines upon 
administration, thus reducing their biological activity. Although no specific animal models 
have been recommended for testing PEG antigenicity, it is important to monitor the patients 
for the presence of anti-PEG antibodies prior to and during the administration of PEGylated 
nanomedicines 94.   
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 (B) Regulatory toxicity studies: Prior to clinical trials, the authorities require preclinical 
safety and PK evaluation in animals under GLP regulations. As such, the regulatory toxicity 
studies are commonly outsourced to an approved and fully equipped CRO. The nonclinical 
safety assessment for marketing approval of a pharmaceutical usually includes pharmacology 
studies, general toxicity studies, toxicokinetic and nonclinical pharmacokinetic studies, 
reproduction toxicity studies and genotoxicity studies. The nonclinical safety studies should 
be adequate to characterize potential adverse effects that might occur under the conditions of 
the clinical trial to be supported. The choice of the more adequate panel of studies to address 
safety of novel nanosystems should be guided mainly by the dosage expected to be used in 
humans and also by the specific characteristics of the nanoparticles.  
The following toxicology tests are the main ones required before nanomedicinal product trials 
in humans: (a) Safety Pharmacology, a  core battery according to ICHS7A, ICHS7B including  
the assessment of effects on cardiovascular, respiratory and central nervous systems (QT 
prolongation, respiratory function, Irwin Test); (b) Toxicokinetic (TK) and Pharmacokinetic 
(PK) studies to determine plasma PK and elimination, as well as the validation of analysis 
methods in relevant species for repeated dose studies; (c) Acute Toxicity studies, mainly 
based on single dose or expanded acute toxicity studies in 2 mammalian non-primate species. 
Animals are monitored over 14 days for body weight, organ weight indices, as well as 
behavioural, biochemical and histopathological changes. The Maximum Tolerated Dose 
(MTD) and the No Observed Adverse Effect Level (NOAEL) should be obtained; (d) 
Repeated Dose Toxicity studies over 2 weeks (minimum duration), in 2 mammalian species 
(rodent and non-rodent); (e) Local tolerance studies in rabbit, using routes relevant to the 
proposed clinical administration route; (f) Genotoxicity studies including gene mutation 
(Ames Test) and chromosomal damage test (human lymphocytes). The requirement to 
execute this complete panel of tests is related to the effective dose that it is supposed to be 
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used. For instance, not all these tests are required for a PET/SPECT nanosystem for imaging 
using microdoses and a single injection. 
More specific studies should be taken into account with respect to different peculiarity of the 
investigated nanosystems (i.e. iron determination for iron-based nanosystems, rate and 
location of a drug released by a liposome system, etc.). All the above mentioned studies are 
necessary for the evaluation of benefits and risks for patients, but due to the large costs of 
procedures, often constitute a first major financial hurdle for a given nanoproduct. 
  
8. Production scale-up and GMP-compliant synthesis 
Another major hurdle to overcome in the process of approval of a nanomedicine for clinical 
use relates to its scale-up and production under Good Manufacturing Practice (GMP) 
regulation. At many academic institutes, adequate facilities and expertise for scaled-up 
production and manufacturing under GMP are lacking and therefore these activities need to be 
outsourced to a fully licensed manufacturer capable of handling nanomedicinal products. 
Very often significant pharmaceutical development has to be done before a process can be 
scaled up and brought under GMP. A major issue with nanomedicinal products is their 
sterilization, where one is mostly condemned to sterile filtration through 0.2 micrometer 
filters or – if particles are around or larger than 200 nm – needs to implement an aseptic 
manufacturing method, which comes with its own challenges.   
Besides a robust manufacturing process, also the quality control, which includes the release 
specifications of the product and the implementation of the full set of characterization assays 
has to be prepared. All assays have to be verified or qualified before GMP manufacturing.. 
Finally one must ensure that containers, closures and packaging material are of the right 
quality and fully compatible with the product.  
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9. Preparation of regulatory dossiers for local/national authorizations of clinical trials 
involving nanomedicines 
For all pharmaceutical/medicinal products, non-clinical and clinical information has to be 
compiled in the format of an Investigational Medicinal Product Dossier (IMPD) and an 
Investigator’s Brochure (see below). This documentation is required for clinical trial approval, 
as well as for the final product dossier and usually requires the specific expertise of a 
dedicated academic or industrial Contract Research Organization (CRO).  
In order to inject any nanomedicinal product (ranging from a macromolecular assembly to a 
complex nanoparticulate structure loaded with drug and/or contrast agent) in humans, several 
steps have to be followed, in accordance with the specific guidelines (manufacture of sterile 
medicines, manufacture of experimental drugs and manufacture of radiopharmaceuticals). The 
first step involves the IMPD preparation. This document compiles all information related to 
the drug substance (Part S) and the investigational medical product under test (Part P). The 
drug substance can be a natural or a synthetic compound, and the product is the 
nanoformulation of the drug. 
Part S describes 1) the origin and the structure of the drug substance, 2) its manufacturing 
process and process controls, 3) the control of materials and critical steps, 4) its composition 
and the impurities, 5) the full control of the drug substance (specifications, analytical 
procedures, validation of analytical procedures, batch analyses, justification of specifications), 
6) the container closure system, 7) the stability under long term and accelerated storage 
conditions. Part P describes the nanoformulation of the drug and the pharmaceutical 
development, as well as the same information as in Part S except an additional specific 
control of excipients. For the development of a radiopharmaceutical for PET or SPECT 
imaging-based diagnostics, an additional IMPD Part P has to be completed. The reason for 
this is that the cold nanoformulation of the drug described in the IMPD Parts S and P is not 
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the final product to be injected into humans, so that the final formulation with the added 
radionuclide is considered as a new medicinal product under test. 
The second document to be completed is the Investigator’s Brochure composed of 5 chapters 
that assemble all the non-clinical and clinical information available about the investigational 
product that is relevant in the outlook of administration to human subjects. The first chapter is 
a short review that deals with the biological properties of the medical product and their effects 
in humans in accordance with the medical indications. The second chapter is a summary of 
the main results of the IMPD Part S and P. The third chapter contains a scientific description 
of all the preclinical results (in vitro and in vivo pharmacology; biodistribution, 
pharmacokinetics and dosimetry, if necessary). In addition, a special focus is placed on a 
battery of toxicology studies: acute oral toxicology, extended single dose toxicity, CARPA, 
and genotoxicity. The fourth chapter compiles all the data obtained previously in humans with 
the use of the investigated medical product. The last chapter provides the investigators with a 
guidance summarizing the information essential for a clinical study (therapeutic indications, 
posology and administration route, contra-indications, special warnings, reference safety 
information). 
Finally, the interventional research protocol (study protocol) and a dedicated document 
dealing with information to be specified for clinical trials on first administration in humans (if 
necessary) have to be prepared. The study protocol should indicate the scientific justification 
for the trial, the objectives, a description of the trial, the procedure of the trial and eligibility 
criteria, the treatment administered to study participants, and the efficacy assessment. 
Furthermore, this document must contain information regarding regulatory issues such as 
specific committees for the trial, safety assessment (risks and restrictions added by the study), 
data management, statistical aspects, quality control and insurance, ethical and legal 
considerations, as well as funding and insurance issues. 
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The national competent authority issues a clinical trial authorization upon reviewing study 
protocol and the Investigator’s Brochure. The content and format of the protocol must comply 
with Community guideline on Good Clinical Practice (CPMP/ICH/135/95). In parallel, the 
subject information leaflet and informed consent form are prepared, informing the patients on 
the nature, scope and possible consequences of the study. These must be in language and 
terms understandable to the participants. Local authorization of clinical trials is obtained 
through institutional ethical committees based on the submitted study protocols, the case 
report forms, subject information leaflet and informed consent forms, according to the 
National and European legislation (Helsinki, National codes of Public Health, the principles 
Good Clinical Practice (GCP), Bioethics law, European Dir. 95/46/CE) (Figure 5).  
 
Figure 5. List of regulatory documents to prepare and submit for national authorization of 
phase 1 clinical trials. 
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10. Clinical adoption challenges  
The implementation of new technologies in healthcare faces multiple challenges, including 
institutional interests, availability of appropriate infrastructure and clinical skills for preparing 
patients and their treatment, the administration and the monitoring of treatment outcomes, the 
enrolment of patients in the clinical trials and theevaluation and acceptance endpoints 95, and 
last but certainly not least, country-specific reimbursement structures and affordability. Thus, 
recent experience with the biologicals (PCSK9-antibodies) has taught that even highly 
effective and safe interventions 96 will be implemented at a low pace, if the price is considered 
to be out of balance with the offered advantages. Studies in several EU member states 
concerning the attitudes of the public to nanomedicine revealed a global support, because 
nanotechnology in medicine is expected to bring medical progress, but the potential for safety 
risks is also often cited 97, 98. However, the perception of risks differs very significantly 
between the use of industrial nanomaterials (generally of inorganic nature) and the use of 
medical nanomaterials. Despite the fact that the regulation, control and approval between the 
two categories of nanomaterials are very different, with an incomparably more stringent 
regulation in nanomedicine, the implementation of technologies that involve significant use of 
manufactured nanoparticles may face resistance from those patients who perceive 
nanotechnologies to be associated with unseen future risks 99. This implies a need to engage 
with the public and especially with patients’ organisations as the introduction of 
nanomedicinal products proceeds 100. Interaction should be sought already at an early stage 
with relevant patients’ organisations and also with medical staff who would eventually 
become the end users of the nanomedicines. The contact to patients' organisations can be 
established before or during designing clinical trials, but care is needed to ensure that the 
safety aspects are sensitively handled, and that sufficient support and information is provided 
to patients and carers.  
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To create a platform for dissemination among the patients’ communities and the general 
public, within the scope of the NanoAthero project Edinetics Ltd. developed the Democs card 
game entitled “Nanomedicine for Atherosclerosis”, which provides an inexpensive and 
entertaining way to engage, inform and discuss the benefits and risks of novel nanomedicines 
with a broader public. 
 
11. Summary and conclusions 
The potential clinical impact of nanotechnology in terms of CVD diagnosis, management and 
risk assessment to ultimately reduce the global disease burden cannot be overestimated. The 
translation of basic studies into clinical trials clearly represents the biggest challenge in this 
field, because developing and bringing a novel nanomedical product to the clinic is a process 
that involves multidisciplinary efforts of biologists, chemists, pharmacists, bio-engineers and 
clinicians (Fig. 6), and requires strong expertise in safety issues, healthcare structures, GMP-
compliant production and marketing. 
  
Figure 6. Multidisciplinarity in nanomedicine. Bringing the nanomedicinal product into the 
clinic requires cooperative efforts of experts from different areas of science, technology, 
healthcare and industry. 
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Whereas about 20% of the approved nanodrugs are indicated for the treatment of cancer, 
according to current estimates14, 17, cardiovascular nanomedicines represent about 1% of the 
market. While approved anti-cancer nanomedicines generally alter the toxicological profile of 
the encapsulated drugs in patients, they do not really enhance local antitumor efficacy, which 
allegedly results from poor, erratic and heterogenous drug delivery in tumor tissues101. Indeed, 
given the high medical need, the translational hurdle is generally lower for anti-cancer 
nanomedicines, but the absence of a real breakthrough in terms of improved drug delivery and 
anti-tumor effect may slow down the momentum in the development of nanomedicines for 
other indications. It is clear that the clinical relevance of nanomedicine, both in oncology and 
cardiology, will depend on rational design of particles for which sufficient delivery to target 
tissues can be ensured101. For this purpose, extensive fundamental studies on nanoparticle 
interactions with vascular endothelium in the presence of blood cells will be essential to 
determine the relationship between physicochemical properties of nanoparticles and their 
delivery efficiency. In terms of safety, cardiovascular nanomedicine is further expected to 
benefit from standardized definitions and clear guidelines, but also from reliable, interference-
free assays serving as nanotoxicity screening tools.  
Addressing the key steps in the process of nanomedicinal product translation (Table 1 and 2), 
this article intends to help researchers and clinicians better understand the development 
hurdles and regulatory requirements concerning new (nano)medicines, highlighting the 
tension that exists between these complexities on the one hand and the feasibility and 
affordability desired by the cardiovascular clinical arena on the other hand. As many early-
stage innovative nanomedicine development efforts take place within academia, beyond the 
large R&D budgets of the pharmaceutical industry, there can only be hope that more funding 
options become available in the field of CVD to perform systematic basic studies concerning 
the mechanisms of nanoparticle transport, their interactions with cells and disease targeting 
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efficacy that should in the future guide their improved design. Large scale funding and/or 
pharmaceutical industry investments will be necessary to help promising new nanomedicinal 
drug products reach the clinical stage in which proof of efficacy and added therapeutic benefit 
can really be shown in patients.  
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Table 1. Translation checklist  
Development step Performed (Y/N) Qualified (Y/N) 
Characterization and physicochemical evaluation 
Size and charge analysis   
Dispersibility analysis in complex media   
Degradation products analysis   
Stability and shelf life   
Costs analysis   
Manufacturability and scale-up   
Sterisability, pyrogen content check   
In vitro safety 
Target cell response analysis   
First-contact cell response   
Hemolytic response   
Immune response   
Thrombogenicity analysis   
In vivo evaluation 
In vivo efficacy in appropriate animal model   
CARPA   
Biodistribution   
Regulatory toxicology and PK   
GMP-compliant production 
Scale-up   
GMP synthesis   
Approval for clinical use 
IMPD, preparation of regulatory dossiers   
Ethical approval   
Evaluation of clinical adoption readiness    
CARPA, complement activation-related pseudoallergy; GMP, good manufacturing practice; 
IMPD, investigational medicinal product dossier. 
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Table 2. Barriers to translation and possible mitigation steps. 
Barrier to translation Mitigation steps 
Approval for novel nanomaterials/nanoparticle use 
in humans is challenging compared with small 
molecules 
 A clear rationale is required demonstrating the advantages of novel nanoparticles over 
established diagnostic/therapeutic agents, e.g. site-directed drug delivery, thus ensuring 
maximal therapeutic outcome while minimizing potentially negative systemic side 
effects or the ability to monitor drug release/efficacy through a nanoparticle carrier plus 
imaging modality (theranostics). 
 Designing nanoparticles with materials that have a history of use in humans and are 
easily modifiable for tailored use such as lipid or polymeric nanoparticles, more viable 
candidates for regulatory approval. Indeed, the first diagnostic imaging nanoparticle 
(64Cu-25%-CANF-Comb) to be utilized for imaging atherosclerotic plaque stability  was 
polymeric based and entered phase 0 human trials (ClinicalTrials.gov Identifier: 
NCT02498379) via an exploratory investigative new drug application (eIND) pathway. 
 Designing theranostic/therapeutic nanoparticles with similar specifications to those 
already FDA approved for clinical trials (e.g. AuroLase®) may expedite approval, 
especially if classified as a medical device rather than a medicinal product. 
 Directing nanoparticles towards improved therapeutic responses in disease patients may 
prove more favourable to regulatory authorities (where side-effects may be more 
acceptable) than use as a diagnostic tracer in the healthy population. 
 Diagnostic use where the target population are patients with disease states that have 
progressed to life-threatening, where improved diagnostic information may allow earlier 
and robust therapeutic intervention when all other options have expired may offer a 
more acceptable first clinical use. 
Regulatory approval for diagnostic imaging agents 
has, to date, been limited to trace amounts 
 For diagnostic imaging, nanomaterials should display high avidity for target combined 
with a high sensitivity imaging modality so that administered concentrations are low. 
 The lack of toxicity demonstrated by a low level nanomaterial dose in humans coupled 
with successful diagnostic/therapeutic outcomes may facilitate more rapid routes (e.g 
exploratory investigative new drug application (eIND) pathway in the US) to in-human 
use with further agents of a similar design, e.g. same core nanoparticle but with a 
different targeting ligand. Currently eIND pathways (phase 0 trials) for diagnostic 
imaging agents are restricted to PET probes as exampled above. 
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Potential toxicity of nanomaterials  Use biodegradable and inert components, preferably with a prior use in humans, e.g. 
liposomes, polymeric particles. Potentially immunogenic components should be 
protected by a biocompatible shell e.g. via pegylation. 
 Ensure physiochemical properties, e.g. pH, charge are optimized for in vivo use. 
 Perform sterilization procedures that adhere to regulatory guidelines. 
 Initial studies should be done in cell culture to ascertain stability/possible aggregation in 
serum containing fluids and potential toxicity on cells. The extensive testing of agents 
on human endothelial cells under static and flow conditions is a necessity as endothelial 
cells would be the first point of contact for any nanomaterial administered 
intravascularly. Successful results in cell culture would be followed by safety testing in 
animals including the CARPA test in pigs and toxicology/immunogenicity studies in 
rodent and non-rodent species. 
 Initial human studies may involve local delivery (e.g. topical or intra-colon) to avoid 
systemic distribution and demonstrate lack of adverse events before systemic 
administration. 
Insufficient standardization between pre-clinical 
studies 
 If pre-clinical data sets are generated at multiple institutions, common standard 
operating protocols must be in place including identical nanomaterial properties, 
experimental methodology and data acquisition/analysis as required for new drug 
applications. This sharing of expertise rather than trying to do everything ‘in house’ 
allows the more rapid acquiring of these pre-requisite robust data sets. 
 Manufacturing should take place in GLP facilities with an external independent partner 
facility validating quality control. Multiple analytical methods should be used to validate 
that the finished product meets desired specifications. Each batch must conform to 
desired specifications to have confidence in the safety/efficacy profile of the finished 
product. 
Cost of manufacturing/upscaling production  Careful consideration should be given to simplifying, where possible, the manufacturing 
process and optimizing methodology that can be outsourced to a manufacturer for 
upscaling production without compromising the properties of the final product. 
 Adequate sterilization and analytical methods suitable to nanoparticle size agents must 
be validated and implemented. 
Nanoparticles do not maintain original 
physiochemical/biological properties over time 
 Perform, early in the development stage, characterization of nanoparticles at multiple 
time points up to 1 year following storage at 4° to ensure stability. 
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precluding clinical use 
Prolonged bioaccumulation in organs associated 
with nanoparticle elimination such as liver, spleen 
or kidney 
 Detailed pharmacokinetic analysis including temporal and dose-response to monitor 
nanoparticle concentrations in different tissue compartments e.g. full body 
autoradiography and ex vivo tissue section assessment. 
Agents do not meet expectations of efficacy  Careful selection of animal models with clinical grade data acquisition equipment can 
minimize likelihood of failure. Where possible, the use of large animal models (e.g. 
porcine) combined with a clinical specification imaging platform e.g. 3T MRI should be 
used for more representative and translatable data. 
Lack of clinical adoption/market value  Design nanomaterials that target key unmet clinical needs such as earlier and improved 
diagnosis, monitoring disease progression or the efficacy of therapeutics. Benefits 
arising from this added clinical value would include improved patient outcomes, 
reduced diagnostic costs, reduced physical and emotional burden on patients and further 
cost savings to Health Authorities via the reduced demand for surgery and ineffective 
treatments due to improved decision-making arising from new diagnostic information. 
 Nanomaterials targeted to common disease biomarkers are likely to find more 
widespread use (and ultimately greater financial reimbursement) compared with 
nanomaterials targeted to less well defined disease markers. 
 Creating nanomaterials that can outperform current small molecular tracers, e.g. longer 
circulation times for improved target binding allowing visualization of new disease 
markers for diagnostic/therapeutic targeting. 
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